Vol 27, No 4 (2020)
Published online: 2020-09-10

open access

Page views 909
Article views/downloads 900
Get Citation

Connect on Social Media

Connect on Social Media

The legacy of ISCHEMIA

Umberto Ianni1, Francesco Radico1, Fabrizio Ricci2, Matteo Perfetti3, Federico Archilletti1, Giulia Renda1, Nicola Maddestra3, Sabina Gallina2, Marco Zimarino1
Pubmed: 32929700
Cardiol J 2020;27(4):329-335.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Maron D, Hochman J, Reynolds H, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020; 382(15): 1395–1407.
  2. Spertus J, Jones P, Maron D, et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020; 382(15): 1408–1419.
  3. Boden WE, O'Rourke RA, Teo KK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15): 1503–1516.
  4. Al-Lamee R, Thompson D, Dehbi HM, et al. ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391(10115): 31–40.
  5. Maron DJ, Hochman JS, O'Brien SM, et al. ISCHEMIA Trial Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018; 201: 124–135.
  6. Shaw LJ, Berman DS, Maron DJ, et al. COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117(10): 1283–1291.
  7. Shaw LJ, Berman DS, Picard MH, et al. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging. 2014; 7(6): 593–604.
  8. Maron D, Harrington R, Hochman J. Planning and Conducting the ISCHEMIA Trial. Circulation. 2018; 138(14): 1384–1386.
  9. Shaw L, Nagel E, Salerno M, et al. Cardiac Imaging in the Post ISCHEMIA Trial Era - A Multi Society Viewpoint. JACC: Cardiovasc Imaging. 2020.
  10. Jang JJ, Bhapkar M, Coles A, et al. PROMISE Investigators. Predictive model for high-risk coronary artery disease. Circ Cardiovasc Imaging. 2019; 12(2): e007940.
  11. Ge Y, Pandya A, Steel K, et al. Cost-Effectiveness analysis of stress cardiovascular magnetic resonance imaging for stable chest pain syndromes. JACC Cardiovasc Imaging. 2020; 13(7): 1505–1517.
  12. Murthy VL, Eagle KA. ISCHEMIA: A Search for clarity and why we may not find it. Am Heart J. 2018; 203: 82–84.
  13. Cortés C, Johnson TW, Silber S, et al. ISCHEMIA trial: the long-awaited evidence to confirm our prejudices. Cardiol J. 2020.
  14. Antman EM, Braunwald E. Managing stable ischemic heart disease. N Engl J Med. 2020; 382(15): 1468–1470.
  15. Koskinas KC, Ndrepepa G, Räber L, et al. Prognostic impact of periprocedural myocardial infarction in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Interv. 2018; 11(12): e006752.
  16. Stone G, Kappetein A, Sabik J, et al. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019; 381(19): 1820–1830.
  17. Ben-Yehuda O, Chen S, Redfors B, et al. Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. Eur Heart J. 2019; 40(24): 1930–1941.
  18. Zannad F, Rossignol P. Cardiovascular outcome trials in patients with advanced kidney disease: time for action. Circulation. 2017; 135(19): 1769–1771.
  19. Bangalore S, Maron DJ, O'Brien SM, et al. ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020; 382(17): 1608–1618.
  20. Bajaj NS, Singh A, Zhou W, et al. Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment. Circulation. 2020; 141(1): 21–33.
  21. Reynolds HR. Natural history of symptoms and stress echo findings in patients with moderate or severe ischemia and no obstructive CAD (INOCA): the NHLBI-funded CIAO ancillary study to the ISCHEMIA trial. ACC 2020, March 30, 2020.
  22. Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. Eur Heart J. 2018; 39(23): 2135–2146.
  23. Garcia S, Sandoval Y, Roukoz H, et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol. 2013; 62(16): 1421–1431.
  24. Zimarino M, Ricci F, Romanello M, et al. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. Catheter Cardiovasc Interv. 2016; 87(1): 3–12.
  25. Zimarino M, Curzen N, Cicchitti V, et al. The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol. 2013; 168(3): 1748–1757.
  26. Lee HS, Lee JM, Nam CW, et al. Consensus document for invasive coronary physiologic assessment in Asia-Pacific countries. Cardiol J. 2019; 26(3): 215–225.
  27. Gutiérrez-Chico JL, Chen Y, Yu W, et al. Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. Cardiol J. 2020 [Epub ahead of print].
  28. Gutiérrez-Chico JL, Louvard Y. DECISION-CTO: A "negative" clinical trial? Really? Cardiol J. 2017; 24(3): 231–233.
  29. Zimarino M, Briguori C, Amat-Santos IJ, et al. Mid-term outcomes after percutaneous interventions in coronary bifurcations. Int J Cardiol. 2019; 283: 78–83.
  30. Werner GS, Martin-Yuste V, Hildick-Smith D, et al. EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018; 39(26): 2484–2493.
  31. Giustino G, Chieffo A, Palmerini T, et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016; 68(17): 1851–1864.
  32. Zimarino M, Renda G, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs. 2005; 65(6): 725–732.
  33. Zimarino M, Corcos T, Favereau X, et al. Rotational coronary atherectomy with adjunctive balloon angioplasty for the treatment of ostial lesions. Cathet Cardiovasc Diagn. 1994; 33(1): 22–27.
  34. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  35. Al-Lamee R, Jacobs AK. The ISCHEMIA Trial: Was it Worth the Wait? Circulation. 2020 [Epub ahead of print].